Journal of Controlled Release最新文献

{"title":"Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review","authors":"Bakr Ahmed ,&nbsp;Nitika Saini ,&nbsp;Veluchamy A. Barathi ,&nbsp;Vandana B. Patravale ,&nbsp;Rohan M. Shah ,&nbsp;Indu Pal Kaur","doi":"10.1016/j.jconrel.2025.113992","DOIUrl":"10.1016/j.jconrel.2025.113992","url":null,"abstract":"<div><h3>Topic</h3><div>This systematic review explores solid lipid nanoparticles (SLNs) as innovative drug delivery systems for ocular applications. It evaluates their ability to improve bioavailability, sustain drug release, and overcome ocular barriers in treating anterior and posterior segment disorders such as dry eye syndrome, glaucoma, infections, and retinal diseases. Comparisons with traditional delivery systems and other nanoparticle platforms are also addressed.</div></div><div><h3>Clinical relevance</h3><div>Ocular diseases often face challenges in effective drug delivery due to the eye's unique anatomy and physiological barriers. Current treatments, including eye drops and intravitreal injections, are limited by rapid clearance, invasiveness, and systemic side effects. SLNs offer a next-generation alternative, addressing these limitations with enhanced corneal permeability, drug retention, and targeted delivery.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted across PubMed, Scopus, Web of Science, and Google Scholar, focusing on studies and patents published from 2010 to 2024. Inclusion criteria targeted original studies using SLNs for ocular applications, excluding studies describing only liposomes and micelles. The PRISMA 2020 guidelines were followed, and data extraction included active pharmaceutical ingredients (APIs), particle size, zeta potential, and therapeutic outcomes. Risk of bias was evaluated using appropriate frameworks.</div></div><div><h3>Results</h3><div>Twenty-eight (28) studies and twenty (20) patents met inclusion criteria, covering SLNs encapsulating APIs such as econazole, atorvastatin, and cannabinoids. Key findings highlighted enhanced bioavailability (up to 12-fold in vitreous humour for atorvastatin-SLNs), sustained release (24-96 h), and improved corneal permeability (up to 287 % higher than controls). Patented formulations incorporated cationic SLNs, PEGylated lipid nanoparticles, and bioactive-loaded SLNs, demonstrating superior stability and therapeutic efficacy. No significant ocular toxicity was observed across <em>in vitro</em> and <em>in vivo</em> studies.</div></div><div><h3>Conclusion</h3><div>SLNs represent a transformative approach for ocular drug delivery, combining safety, scalability, commercial viability, and enhanced therapeutic outcomes due to higher permeability and controlled release. However, challenges remain in industrial translation and regulatory approvals. Future research should focus on quality by design (QbD) formulation development; simple, viable, energy-efficient, and preferably organic solvent-free methods of preparation; and leveraging advanced characterization techniques like SAXS and molecular simulations to refine and define SLNs design, molecular structure, and function.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113992"},"PeriodicalIF":10.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical cancer nanomedicines","authors":"Roger M. Pallares,&nbsp;Roman A. Barmin,&nbsp;Alec Wang,&nbsp;Fabian Kiessling,&nbsp;Twan Lammers","doi":"10.1016/j.jconrel.2025.113991","DOIUrl":"10.1016/j.jconrel.2025.113991","url":null,"abstract":"<div><div>Over the past three decades, nanomedicines have become increasingly common in the treatment of cancer. By altering the pharmacokinetics and biodistribution profiles of drugs, nanomedicines help to reduce toxicity and enhance overall therapeutic indices. This manuscript reviews the current landscape of nanomedicines for cancer therapy, highlighting the formulations that have successfully reached clinical use as well as those being investigated in clinical trials. These formulations include “conventional” nanomedicines that rely on passive drug delivery, as well as newer formulations that are stimuli-responsive, actively targeted, used for combination therapies, or intended to improve immunotherapy. By critically analyzing the clinical progress of nanomedicines, we aim to identify the key features that drive successful translation and lead to clinical impact.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113991"},"PeriodicalIF":10.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iridium cluster/hafnium-porphyrin framework heterojunctions for biocatalytic ROS-scavenging and acute kidney injury alleviation","authors":"Xinyao Luo ,&nbsp;Shanshan Chen ,&nbsp;Zhuyun Zhang ,&nbsp;Yiyuan Wang ,&nbsp;Yupei Li ,&nbsp;Wenjie Shao ,&nbsp;Hongju Zhou ,&nbsp;Baihai Su ,&nbsp;Chong Cheng","doi":"10.1016/j.jconrel.2025.113993","DOIUrl":"10.1016/j.jconrel.2025.113993","url":null,"abstract":"<div><div>The clinical treatments of acute kidney injury (AKI) face significant challenges from complex microenvironments caused by excessive reactive oxygen species (ROS) and severe inflammation. Up to now, effective treatments remain scarce. In this study, we propose a versatile and effective biocatalytic heterojunction, Ir@Hf-TCPP, developed by growing iridium clusters on hafnium-tetrakis (4-carboxyphenyl) porphyrin (Hf-TCPP) through a readily accessible solvothermal approach. The metal‑oxygen bonds between the Ir clusters and Hf-TCPP ensure structural stability and adequate exposure of the surface active sites. Moreover, such interfacial features can efficiently accommodate the electronic structure of Ir@Hf-TCPP through the electronic interaction of the formed Hf-O-Ir bridge and boost the biocatalytic antioxidase-like performance. As a result, the optimized Ir@Hf-TCPP antioxidant demonstrates robust and broad-spectrum ROS scavenging performance, providing cytoprotective effects by enhancing endogenous antioxidant defense and maintaining mitochondrial homeostasis in renal tubular epithelia. In a murine rhabdomyolysis-induced AKI model, Ir@Hf-TCPP significantly ameliorated kidney injury by suppressing the MEKK1/JNK/p38 signaling pathway. Additionally, the Ir@Hf-TCPP exhibited effective renal accumulation and excellent biocompatibility <em>in vivo</em>. The beneficial impact and favorable biocompatibility of Ir@Hf-TCPP will promote the management of AKI and other ROS-associated diseases.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113993"},"PeriodicalIF":10.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of microbubble cavitation in theranostic ultrasound-mediated blood-brain barrier opening for gene delivery","authors":"Fotios N. Tsitsos ,&nbsp;Alec J. Batts ,&nbsp;Daniella A. Jimenez ,&nbsp;Craig A. Macsemchuk ,&nbsp;Chunqi Li ,&nbsp;Robin Ji ,&nbsp;Sua Bae ,&nbsp;Gillian L. Ciaccio ,&nbsp;Angeliki Theodorou ,&nbsp;Rashell K. Ramirez ,&nbsp;Samantha L. Gorman ,&nbsp;Chloe L. Lugg ,&nbsp;Elisa E. Konofagou","doi":"10.1016/j.jconrel.2025.113986","DOIUrl":"10.1016/j.jconrel.2025.113986","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale&lt;/h3&gt;&lt;div&gt;The characterization of microbubble (MB) activity in ultrasound-mediated blood-brain barrier (BBB) opening has proven critical in assessing the method's safety and efficacy in drug delivery. In this study, we build upon our previous work on theranostic ultrasound (ThUS)-mediated BBB opening (ThUS-BBBO) and conduct for the first time a comprehensive characterization of the role of MB cavitation in ThUS-BBBO and gene delivery with adeno-associated viruses (AAV).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A repurposed diagnostic ultrasound imaging phased array was used to generate ultra-short focused transmits at 1.5 MHz center frequency and simultaneously record acoustic emissions. MB activity was first characterized using a separate passive cavitation detector (PCD) in a flow phantom using pulse lengths ranging from 1.5 to 20 cycles and varying MB flow rates. A comprehensive &lt;em&gt;in vivo&lt;/em&gt; study in mice was then conducted to characterize and correlate the resulting cavitation with AAV transgene expression. The transcranial MB activity was first detected using a PCD to confirm the findings of the flow phantom study. Next, three mouse studies were conducted to evaluate the relationship between cavitation and AAV delivery; one with different MB size distributions including polydisperse and size-isolated MB, one with variable burst length and burst repetition frequency, and one with different AAV serotypes and injection doses. Electronic beam steering enabled bilateral BBB opening with 1.5 cycle on the left and 10 cycles on the right hemisphere. Cavitation dose, BBBO volume, transgene expression, and histological safety were assessed following each experimental condition.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Frequency domain analysis in the phantoms revealed increasing harmonic cavitation with longer pulses. However, analysis in the time domain showed that longer pulses induce higher MB collapse. In the transcranial &lt;em&gt;in vivo&lt;/em&gt; experiments, the PCD detected increased harmonic cavitation for 10-cycle pulses. The MB study showed that 3–5 μm MB resulted in the largest cavitation doses, BBBO volumes and transgene expression compared to the smaller MB groups. However, non-significant differences in BBBO volume and transgene expression were found when the MB dose was normalized by gas volume. The burst sequence study revealed that shorter bursts and faster burst repetition frequencies induce larger BBBO volumes and AAV transduction due to MB replenishment within the focal volume. Transgene expression was also increased with injection dose, and AAV9 showed the highest brain transduction efficiency compared to AAV2 and AAV5.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The phantom and &lt;em&gt;in vivo&lt;/em&gt; studies showed that the mechanism of ThUS-BBBO is transient cavitation dominant and MB collapse increases with pulse length. Increased cavitation dose resulted in larger BBBO volumes and transgene expression &lt;em&gt;in vivo&lt;/em&gt;. Overall, th","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113986"},"PeriodicalIF":10.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipose stem cell-derived nanovesicles for cardioprotection: production and identification of therapeutic components","authors":"Chenyuan Huang ,&nbsp;Wei Heng Chng ,&nbsp;Yub Raj Neupane ,&nbsp;Yanqiu Lai ,&nbsp;Wenhui Cui ,&nbsp;Mingyuan Yang ,&nbsp;Joy Wolfram ,&nbsp;Suet Yen Chong ,&nbsp;Xiaodong Yu ,&nbsp;Sitong Zhang ,&nbsp;Olga Zharkova ,&nbsp;Gert Storm ,&nbsp;Giorgia Pastorin ,&nbsp;Jiong-Wei Wang","doi":"10.1016/j.jconrel.2025.113989","DOIUrl":"10.1016/j.jconrel.2025.113989","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) derived from stem cells have shown therapeutic benefits in myocardial injury. However, the challenges in their large-scale production and elusive molecular mechanisms underlying their therapeutic effects have been hindering their clinical translation. Here, in a mouse model of myocardial ischemia-reperfusion, EVs isolated from human adipose tissue and EV-like nanovesicles fabricated with adipose stem cells (ADSCs) <em>via</em> a membrane extrusion approach, termed ADSC-derived nanovesicles (ADSC-CDNs), exhibited comparable cardioprotective effects, validating this EV-mimetic strategy. CDNs generated from the human monocytic cell line U937 similarly conferred protection, whereas those from HEK293 cells did not, highlighting the importance of cell source for therapeutic efficacy. microRNA profiling identified miR-24-3p as a predominant therapeutic cargo in ADSC-EVs and ADSC-CDNs. This microRNA upregulates the cytoprotective transcription factor Nrf2, thereby suppressing cardiomyocyte apoptosis. Functional assays also confirmed that miR-24-3p was a key component mediating the cardioprotective effects of those nanovesicles. Importantly, this study introduces a cell-source-dependent, scalable, and high-yield production platform for ADSC-CDNs that preserves molecular cargo profile of the parent cells, ensuring consistent therapeutic content. This EV-mimetic platform is technically feasible and clinically translatable, demonstrating reproducible efficacy in both acute injury and post-infarction recovery phases. Taken together, the defined microRNA cargo and the robust vesicle production strategy highlight the translational potential of ADSC-CDNs as an off-the-shelf cardioprotective therapy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113989"},"PeriodicalIF":10.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective communication with JCR editors in the peer review process","authors":"Honggang Cui ,&nbsp;Ana Beloqui ,&nbsp;Davide Brambilla ,&nbsp;Paolo Caliceti ,&nbsp;Yunching (Becky) Chen ,&nbsp;Laura M. Ensign ,&nbsp;Jong Oh. Kim ,&nbsp;Twan Lammers ,&nbsp;Kanjiro Miyata ,&nbsp;Yu-Kyoung Oh ,&nbsp;Dan Peer ,&nbsp;Amirali Popat ,&nbsp;Raymond Schiffelers ,&nbsp;Yang Shi ,&nbsp;Xun Sun ,&nbsp;Pieter Vader ,&nbsp;Yoon Yeo ,&nbsp;Lichen Yin ,&nbsp;Yu Seok Youn ,&nbsp;Zhiyuan Zhong ,&nbsp;Stefaan C. De Smedt","doi":"10.1016/j.jconrel.2025.113973","DOIUrl":"10.1016/j.jconrel.2025.113973","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113973"},"PeriodicalIF":10.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MSC-derived exosomes injectable hyaluronic acid hydrogel for enhanced chronic wound healing","authors":"Hanqing Yu ,&nbsp;Jingyu Zhang ,&nbsp;Liu Yang ,&nbsp;Yufeng Tian ,&nbsp;Cameron Milne ,&nbsp;Peisheng Jin ,&nbsp;Qiang Li ,&nbsp;Rijian Song ,&nbsp;Wenxin Wang","doi":"10.1016/j.jconrel.2025.113985","DOIUrl":"10.1016/j.jconrel.2025.113985","url":null,"abstract":"<div><div>Diabetic chronic wounds are characterized by delayed healing and disrupted immune response. Mesenchymal stem cell-derived exosomes (MSC^Exo) hold significant potential for enhancing wound healing by facilitating intercellular communication, reducing excessive inflammation, and supporting cell proliferation. However, direct application of MSC^Exo to wound sites often results in rapid diffusion and poor retention, limiting their therapeutic efficacy. In this study, we developed a hyaluronic acid (HA)-based injectable hydrogel system to deliver MSC^Exo for treating diabetic chronic wounds. This hydrogel system exhibited excellent cytocompatibility, biodegradability, and skin-like rheology properties. The porous structure of the hydrogel system allows for <em>in situ</em> retention of exosomes, enabling sustained therapeutic effects on the wound. <em>In vitro</em> studies demonstrated that the hydrogels enhanced the proliferation and migration of endothelial cells and fibroblasts. <em>In vivo</em> studies confirmed the hydrogel's ability to accelerate wound closure, enhance angiogenesis, and promote re-epithelialization. This MSC^Exo loaded injectable hydrogel system provides sustained therapeutic benefits and enhances tissue regeneration, presenting a promising clinical strategy for the treatment of chronic diabetic wounds.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113985"},"PeriodicalIF":10.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomicelle with reversible surface properties as a general adjuvant for potentiating immune responses to multiple types of tumor antigens","authors":"Xiaoning Song ,&nbsp;Xinping Luo ,&nbsp;Siqian Ding,&nbsp;Chenxi Zhou,&nbsp;Shan Jiang,&nbsp;Jianbin Pang,&nbsp;Yinuo Fan,&nbsp;Ming Yan,&nbsp;Jie Yu,&nbsp;Fangchun Ding,&nbsp;Minjie Sun,&nbsp;Zhanwei Zhou","doi":"10.1016/j.jconrel.2025.113987","DOIUrl":"10.1016/j.jconrel.2025.113987","url":null,"abstract":"<div><div>Poor antigen presentation efficiency remains the primary challenge of tumor-derived vaccines, mainly due to the inefficient endocytosis of antigens and activation of antigen-presenting cells (APCs). Here, we developed a general ready-to-use adjuvant to enhance the immune response to multiple types of antigens, including tumor cell lysate, tumor cell membrane, antigen protein, and messenger RNA. The adjuvant was synthesised by conjugating cinnamaldehyde onto polyethyleneimine (PC), which self-assembles in the water phase to form nanomicelles. Since the main components of most antigens are proteins or nucleic acids, PC could bind to antigens via hydrophobic or electrostatic interactions and then promote their cellular endocytosis. Notably, in APCs, PC reacted with glutathione (GSH), which not only led to the depletion of GSH and maturation of dendritic cells but also triggered antigen release by reversing the antigen binding force due to GSH's negative charge and hydrophilicity. Thus, the PC adjuvant significantly increased the immunogenicity of tumor cell membranes, tumor cell lysates, and liquid‑nitrogen-shocked tumor cells by 113-, 81-, and 60-fold, respectively, compared to free antigens.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113987"},"PeriodicalIF":10.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poly(thioctic acid)-based supramolecular hydrogels with UV-triggered on-demand H2S release for burn wound healing","authors":"Jueying Chen ,&nbsp;Lipeng Qiao ,&nbsp;Danyu Cheng ,&nbsp;Yutong Yang ,&nbsp;Meng Li ,&nbsp;Xin Zhao ,&nbsp;Baolin Guo","doi":"10.1016/j.jconrel.2025.113983","DOIUrl":"10.1016/j.jconrel.2025.113983","url":null,"abstract":"<div><div>Burn wound complicated by bacterial infection and exaggerated inflammatory response poses a significant threat to patients' lives. Hydrogen sulfide (H₂S) plays a critical role in wound healing, but its application is limited by low carrier loading efficiency and uncontrolled release behavior. Herein, an adhesive, self-healing, and removable supramolecular hydrogel integrating UV-triggered in situ production and on-demand release of H₂S and targeted recognition and killing of bacteria is developed based on poly(thioctic acid) (polyTA), acrylated adenine (AA) and phenylboronic acid-functionalized silver nanoparticles (AgNPs-PBA) to treat burn wound. The hydrogel exhibits high stability, rapid self-healing behavior, highly effective antibacterial activity through a targeted recognition strategy utilizing the boric acid group, adhesive property, UV-shielding property, removability, and on-demand delivery of H₂S, which effectively modulates pro-inflammatory cytokine levels (IL-6, TNF-α, and iNOS). In addition, the hydrogel demonstrates good cytocompatibility and anti-inflammatory, and promotes cell migration. Utilizing full-thickness defects of burns and infected burns, we demonstrated that the combined actions of targeted recognition/killing of bacteria and UV-triggered on-demand release of immunomodulatory H₂S significantly enhanced the burn wound healing process. This adhesive, self-healing, and removable supramolecular hydrogel dressing, with enhanced targeted recognition and killing of bacteria and on-demand in situ H₂S delivery, holds promising application in burn wounds.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113983"},"PeriodicalIF":10.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence","authors":"Shi-Hao Zhou ,&nbsp;Yu-Juan Lei ,&nbsp;Yu Wen ,&nbsp;Dong Ding ,&nbsp;Meng-Qiang Luo ,&nbsp;Hong-Ying Cui ,&nbsp;Jun Guo","doi":"10.1016/j.jconrel.2025.113979","DOIUrl":"10.1016/j.jconrel.2025.113979","url":null,"abstract":"<div><div>Therapeutic vaccines offer promising strategies for cancer treatment, however, the lack of key targets among autologous neoantigens and limited variety of synthetic antigens pose significant challenges. Herein, we developed engineered hybrid membrane vesicles (MVs) as a carrier platform, which combines autologous membrane protein antigens derived from resected tumors with synthetic antigens, aiming to inhibit postoperative tumor recurrence. To enhance antitumor immunity, we utilized an optimized AS01 adjuvant, primarily composed of QS-21 and structurally simplified TLR4 agonist GAP-112, to further enhance the immunogenicity of the autologous and synthetic antigens. This extracellular vesicle (EV)-mimicking therapeutic vaccine platform, which includes P (synthetic peptides), M (autologous membrane proteins), G (GAP112), and Q (QS-21), demonstrates potent antitumor effects and effectively suppressed tumor recurrence in three tumor models, including B16-MUC1, EAC, and B16-OVA tumors. Its mechanisms of immune-enhancement include activating innate immunity, enhancing antigen uptake, and inducing robust antibody and cellular immune responses. These results suggest that this engineered hybrid MVs-based carrier platform holds significant potential as a universal strategy for cancer therapy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113979"},"PeriodicalIF":10.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144371078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}